Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06836232Phase 2Recruiting

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Role: lead

NCT06556173Phase 2Completed

Phase 2a Study of VTX3232 in Parkinson's Disease

Role: lead

NCT06771115Phase 2Completed

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

Role: lead

NCT05812781Phase 2Completed

A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

Role: lead

All 4 trials loaded